SECURITIES AND EXCHANGE COMMISSION
450 Fifth Street, N.W.
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: October 2, 1995
Golden Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware 0-9065 84-0645174
(State of (Commission (IRS Employer
incorporation) File Number) Identification No.)
1313 Washington Avenue, Golden, Colorado 80401
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (303) 279-9375
Not Applicable
(Former Name or Former Address, if Change Since Last Report)
<PAGE>
Item 8. Change In Fiscal Year.
At a meeting of the Audit Committee of the Board of Directors held on
June 3, 1995and ratified by resolutions of the Board of Directors dated
October 2, 1995, the Registrant elected to change its fiscal year from
September 1 through August 31 in each year to January 1through
December 31 in each year, effective immediately.
The report covering the transition period of September 1, 1995 through
December 31, 1995 will be filed as a Quarterly Report on Form 10-Q.
<PAGE>
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GOLDEN PHARMACEUTICALS, INC.
Date: October 2, 1995 By:
Glen H. Weaver, Vice President of
Finance
<PAGE>
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GOLDEN PHARMACEUTICALS, INC.
Date: October 2, 1995 By: /s/ Glen H. Weaver
Glen H. Weaver, Vice President of
Finance
